V212 + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Herpes Zoster
Conditions
Herpes Zoster
Trial Timeline
Jun 24, 2011 → Apr 11, 2017
NCT ID
NCT01254630About V212 + Placebo
V212 + Placebo is a phase 3 stage product being developed by Merck for Herpes Zoster. The current trial status is completed. This product is registered under clinical trial identifier NCT01254630. Target conditions include Herpes Zoster.
What happened to similar drugs?
8 of 20 similar drugs in Herpes Zoster were approved
Approved (8) Terminated (1) Active (11)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01527383 | Phase 2 | Completed |
| NCT01254630 | Phase 3 | Completed |
| NCT00535236 | Phase 1 | Completed |
Competing Products
20 competing products in Herpes Zoster